Avapritinib safety tracked in ongoing mastocytosis patients

NCT ID NCT06748001

Recruiting now Disease control Sponsor: Blueprint Medicines Corporation Source: ClinicalTrials.gov ↗

First seen Dec 10, 2025 · Last updated May 16, 2026 · Updated 23 times

Summary

This study is for people with systemic mastocytosis who have already been taking avapritinib and benefiting from it. Researchers want to see how safe the drug is over a longer period of time by tracking serious side effects. About 60 participants will continue their treatment and be monitored closely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASTOCYTOSIS, SYSTEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno
RECRUITING

Salerno, 84131, Italy
Erasmus Medisch Centrum
RECRUITING

Rotterdam, 3015, Netherlands
Guys and St Thomas NHS Foundation Trust - St Thomas Hospital
RECRUITING

London, SE19RT, United Kingdom
Oslo University Hospital
RECRUITING

Oslo, 0424, Norway
The Hospital for Sick Children
RECRUITING

Toronto, Ontario, M5G 1X8, Canada
Universitair Medisch Centrum Groningen
RECRUITING

Groningen, 9700, Netherlands
Universitair Ziekenhuis Antwerpen (UZA)
RECRUITING

Edegem, 2650, Belgium

Conditions

Explore the condition pages connected to this study.

MASTOCYTOSIS, SYSTEMIC